[Special Stock] Rigakem Bio, Janssen Option Exercise Possibility... New Drug Candidate Value '↑'

Ligacembio is showing strong performance. It appears that securities firms' analysis, which highlights the increasing value of the new drug candidate LCB84 licensed out to Janssen, has had an impact.

As of 10:43 AM on the 19th, Ligacembio was trading at 94,600 KRW, up 5,400 KRW (6.05%) compared to the previous trading day.

Junyoung Kim, a researcher at Meritz Securities, evaluated that competing companies' drug developments have achieved "ambiguous results." He explained, "The clinical results of AstraZeneca's Dato-Dxd, revealed at the World Lung Cancer Conference (WCLC) 2024, were a half-success," adding, "The Phase 1 clinical trial results of LCB84, scheduled for confirmation in 2025, are a crucial moment."

Previously, in December 2023, Ligacembio signed a technology licensing contract worth 1.7 billion USD with Janssen for LCB84 at the Phase 1 clinical trial entry stage.

He analyzed, "It is expected that additional results for LCB71 will be confirmed through the American Society of Hematology (ASH) in December, and depending on the results, the possibility of new drug success can be assessed more closely," adding, "If Janssen exercises the sole development option based on the Phase 1 clinical trial results of LCB84, the company will receive 260 billion KRW."

This content was produced with the assistance of AI translation services.